SCIENCE AND TECHNOLOGY

We work on drug discovery by combining our proprietary global top level antibody engineering and cyclic peptide technology and biological hypothesis of disease causing mechanism to solve the unmet medical needs.

T-Cell Redirecting Antibody

T-Cell Redirecting Antibody is a bispecific antibody for cancer immunotherapy, which binds to tumor antigen and CD3 expressed on the T cell to redirect T cells to potently kill tumor antigen expressing cancer cells. Our first T-Cell Redirecting Antibody, ERY974, is now being tested in clinical study, and we have multiple T-Cell Redirecting Antibody projects in the drug discovery stage.

Reference Article:

An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors

Sci Transl Med. 2017 Oct 4;9(410):eaal4291.

< Back